Baseline characteristics for the study cohort
| General population | RA | DM | RA + DM | |
|---|---|---|---|---|
| Participants (n) | ||||
| Women (%) | 2 046 304 (51.4) | 7011 (70.7) | 59 989 (46.3) | 337 (60.6) |
| Men (%) | 1 932 517 (48.6) | 2910 (29.3) | 69 670 (53.7) | 219 (39.4) |
| All (%) | 3 978 821 (100) | 9921 (100) | 129 659 (100) | 556 (100) |
| Age (years) | ||||
| Women | 47.6 (19.8) | 56.2 (15.9) | 57.1 (18.0) | 61.6 (12.9) |
| Men | 44.6 (18.0) | 56.8 (14.6) | 56.4 (14.3) | 61.3 (11.7) |
| All | 46.1 (19.0) | 56.4 (15.5) | 56.7 (16.1) | 61.5 (12.4) |
| Charlson's comorbidity index | ||||
| Women | 0.02 (0.23) | 0.02 (0.16) | 0.04 (0.28) | 0.05 (0.33) |
| Men | 0.02 (0.22) | 0.02 (0.16) | 0.04 (0.28) | 0.03 (0.22) |
| All | 0.02 (0.22) | 0.02 (0.16) | 0.04 (0.28) | 0.04 (0.29) |
| Socioeconomic index | ||||
| Women | 1.60 (1.29) | 1.48 (1.30) | 1.31 (1.26) | 1.20 (1.22) |
| Men | 2.45 (1.40) | 2.49 (1.33) | 2.27 (1.41) | 2.29 (1.39) |
| All | 2.01 (1.41) | 1.78 (1.39) | 1.83 (1.43) | 1.63 (1.40) |
| Baseline cardioprotective therapy (n) | ||||
| β blocker (%) | 126 636 (3.2) | 516 (5.2) | 11 212 (8.6) | 54 (9.7) |
| Statin (%) | 17 136 (0.4) | 71 (0.7) | 1978 (1.5) | 9 (1.6) |
| ACEI/ARB (%) | 88 927 (2.2) | 392 (4.0) | 10 384 (8.0) | 47 (8.5) |
| Loop diuretic (%) | 106 371 (2.7) | 420 (4.2) | 9662 (7.4) | 58 (10.4) |
| Spironolactone (%) | 12 247 (0.3) | 45 (0.5) | 1335 (1.0) | 8 (1.4) |
| Vitamin K antagonist (%) | 17 471 (0.4) | 93 (0.9) | 1630 (1.3) | 15 (2.7) |
| Platelet inhibitor (%) | 117 116 (2.9) | 438 (4.4) | 8976 (6.9) | 48 (8.6) |
Values stated as means (SD) unless otherwise indicated.
ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin 2 receptor blockers; DM, diabetes mellitus; IRR, incidence rate ratio; RA, rheumatoid arthritis.